Cadence Pharmaceuticals Appoints Michael L. Eagle to its Board of Directors

Cadence Pharmaceuticals Appoints Michael L. Eagle to its Board of Directors

SAN DIEGO, March 29, 2010 /PRNewswire via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today the appointment of Michael L. Eagle to the company's board of directors.

"We are very pleased to welcome Mike Eagle to our board of directors," stated Cam Garner, Chairman of Cadence. "With more than 35 years of experience in executive management and engineering, primarily focused on the manufacture of pharmaceutical products and medical devices, Mike will be an excellent addition to our board. We all look forward to working with him as we continue to build a world class, hospital-focused biopharmaceutical company."

Mr. Eagle served as Vice President of Manufacturing for Eli Lilly and Company from 1994 through 2001 and held a number of executive management positions with Eli Lilly and its subsidiaries throughout his career. Since retiring from Eli Lilly, he has served as a founding member of Barnard Life Sciences, LLC. Mr. Eagle currently serves on the boards of directors of Somaxon Pharmaceuticals, Inc., a publicly-held specialty pharmaceutical company, Micrus Endovascular Corporation, a publicly-held medical device company, and Cardio Polymers, Inc., formerly known as Symphony Medical, a private medical device company. He serves on the Board of Trustees of the La Jolla Playhouse and Futures for Children. Mr. Eagle earned a B.S. degree in mechanical engineering from Kettering University and an M.B.A. from the Krannert School of Management at Purdue University.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. For more information about Cadence, please visit www.cadencepharm.com.

Cadence(TM) is a trademark of Cadence Pharmaceuticals, Inc.

 

    Contact:    William R. LaRue                   Aimee Corso
                SVP & Chief Financial Officer      Media & Investor Relations
                Cadence Pharmaceuticals, Inc.      WCG
                Phone: 858-436-1400                Phone: 310-780-2661

 

SOURCE Cadence Pharmaceuticals, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.